{
}
With low interest rates likely to persist, the stock market is poised for growth as companies can borrow cheaply to invest. However, geopolitical tensions and uncertainties may lead to volatility in 2025, making high-dividend stocks a safer investment choice for stable returns. The Swiss equity market, known for its defensive nature, features companies like Nestlé and Roche that offer attractive dividends, providing a buffer against market fluctuations.
Regeneron Pharmaceuticals, Inc. focuses on developing and selling drugs for eye and inflammatory diseases and cancer. Its net sales are primarily derived from product sales (56.6%) and collaboration agreements (40.4%), with significant partnerships with Sanofi, Bayer, and Roche. The company has around 35 products in clinical development as of the end of 2022.
Rapt Therapeutics has pivoted after halting its lead program, agreeing to pay $35 million for RPT904, a long-acting anti-IgE antibody in development by Shanghai Jemincare. Targeting food allergies, Rapt aims to start a phase 2b trial next year, anticipating peak U.S. sales of $4.5 billion. Investors have backed the biotech with $150 million, extending its cash runway through the expected delivery of trial data in 2027.
Sangamo Therapeutics saw its shares soar by 36% after Roche announced the discontinuation of its gene therapy program for hemophilia A, specifically the SPK-8011 therapy. This decision, described as a "strategic decision," follows Roche's acquisition of Spark Therapeutics in 2019. Sangamo is collaborating with Pfizer on a competing gene therapy, giroctocogene fitelparvovec, targeting the same condition.
AbbVie's schizophrenia drug emraclidine failed two mid-phase trials, performing no better than placebo, resulting in a $40 billion market cap loss for the company. This setback follows the recent approval of Bristol Myers Squibb's Cobenfy, the first new schizophrenia drug in decades, which boosted BMS's share price by 12%. The failure raises concerns for other companies developing similar drugs in the same class.
Hookipa Pharma reported a Q3 net loss of $13.8 million, an improvement from $19.1 million a year prior, amid a strategic shift following the termination of a collaboration with Roche. Revenue from collaboration and licensing fell to $4.7 million, down from $6.9 million, while operating expenses decreased to $23.3 million from $29.5 million. The company is actively seeking funding to sustain its development programs and address ongoing financial challenges.
Jean Rochefort
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
stable income through high dividend stocks in uncertain markets
United States Dollar
S Tempo Swiss Life AM
Novartis AG
Swiss Re AG
Zurich, Agence générale Christian Meier SA
Hoffmann-La Roche AG
Nestlé S.A.
CHE
Jean Rochefort
Show more
11:10 27.03.2025
regeneron pharmaceuticals faces downgrade as it focuses on diverse drug portfolio
13:02 16.01.2025
rapt therapeutics acquires long acting anti-ige antibody for food allergy treatment
United States Dollar
Novartis AG
Hoffmann-La Roche AG
RAPT Therapeutics, Inc.
CHN
USA
Jean Rochefort
Show more
14:10 23.12.2024
sangamo shares rise sharply after roche halts hemophilia gene therapy program
21:06 16.12.2024
setbacks in drug development impact schizophrenia and oncology markets
Arcus Biosciences, Inc.
Hoffmann-La Roche AG
Gilead Sciences, Inc.
Biohaven Ltd.
Merck & Co., Inc.
Genentech
Cassava Sciences, Inc.
ABBVIE
Bristol-Myers Squibb Co
BioAge Labs, Inc.
USA
Jean Rochefort
Show more
01:00 16.12.2024
Hookipa Pharma Reports Q3 Loss Amid Strategic Shift and Funding Challenges
05:23 15.11.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Finance Mergers & Acquisitions
Banking Regulations
Global Financial Events
Market Analysis and Predictions
Retail and Consumer Goods
Financial Scams and Security
CEO Changes
Global Trade Developments
Central Bank Actions
GDP Growth & Recession Forecasts
Government Policies
Hedge Funds & Private Equity
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Startups & Entrepreneurship
Workplace Trends
Government Economic Policies
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Bank of America Corporation
Wells Fargo & Company
Citigroup Inc.
Barclays PLC
Morgan Stanley
Deutsche Bank Money Market PP
Lloyds Banking Group plc
Huawei Technologies CO. Ltd.
American Express Company
Credit Suisse Strategic Income I
UBS Group AG
AMERICAN EXPRESS
Northern Trust Corporation
Berkshire Hathaway Inc.
Amazon.com, Inc.
Banco Santander, S.A.
Currencies:
United States Dollar
Euro
Chinese Yuan
Swiss Franc
British Pound Sterling
Indian Rupee
Japanese Yen
Canadian Dollar
Australian Dollar
Russian Ruble
Saudi Riyal
United Arab Emirates Dirham
Indonesian Rupiah
Mexican Peso
Hong Kong Dollar
Danish Krone
Offshore Chinese Yuan
Singapore Dollar
Ghanaian Cedi
South Korean Won
People: